Allison A Eddy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4100551/publications.pdf

Version: 2024-02-01

76326 53230 7,459 93 40 85 citations h-index g-index papers 96 96 96 7376 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nephrotic syndrome in childhood. Lancet, The, 2003, 362, 629-639.	13.7	716
2	Macrophage diversity in renal injury and repair. Journal of Clinical Investigation, 2008, 118, 3522-3530.	8.2	637
3	Molecular basis of renal fibrosis. Pediatric Nephrology, 2000, 15, 290-301.	1.7	555
4	Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney International, 1995, 47, 1546-1557.	5.2	338
5	Progression in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2005, 12, 353-365.	1.4	280
6	PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney International, 2001, 60, 587-596.	5.2	246
7	The NPHP1 Gene Deletion Associated with Juvenile Nephronophthisis Is Present in a Subset of Individuals with Joubert Syndrome. American Journal of Human Genetics, 2004, 75, 82-91.	6.2	228
8	Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2999-3012.	6.1	213
9	Overview of the cellular and molecular basis of kidney fibrosis. Kidney International Supplements, 2014, 4, 2-8.	14.2	193
10	Chronic Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2006, 17, 2964-2966.	6.1	171
11	Plasminogen activator inhibitor-1 and the kidney. American Journal of Physiology - Renal Physiology, 2002, 283, F209-F220.	2.7	166
12	Critical and Honest Conversations. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1664-1672.	4. 5	157
13	Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatric Neurology, 1995, 13, 191-197.	2.1	138
14	Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney International, 2004, 66, S76-S89.	5.2	138
15	Proteinuria and interstitial injury. Nephrology Dialysis Transplantation, 2004, 19, 277-281.	0.7	134
16	Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney International, 1991, 40, 1020-1031.	5.2	132
17	CD36 Regulates Oxidative Stress and Inflammation in Hypercholesterolemic CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 495-505.	6.1	127
18	Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1–overexpressing mice. Kidney International, 2005, 67, 2221-2238.	5.2	124

#	Article	IF	CITATIONS
19	Investigating mechanisms of chronic kidney disease in mouse models. Pediatric Nephrology, 2012, 27, 1233-1247.	1.7	116
20	Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney International, 1988, 33, 14-23.	5.2	111
21	Urokinase Receptor Deficiency Accelerates Renal Fibrosis in Obstructive Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1254-1271.	6.1	111
22	Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective. Kidney International, 2000, 58, 618-628.	5.2	109
23	TIMP-1 Deficiency Does Not Attenuate Interstitial Fibrosis in Obstructive Nephropathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 736-748.	6.1	108
24	Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney International, 1996, 50, 1139-1149.	5.2	100
25	Plasmin(ogen) Promotes Renal Interstitial Fibrosis by Promoting Epithelial-to-Mesenchymal Transition. Journal of the American Society of Nephrology: JASN, 2007, 18, 846-859.	6.1	97
26	Pseudohermaphroditism, glomerulopathy, and Wilms tumor (Drash syndrome): Frequency in end-stage renal failure. Journal of Pediatrics, 1985, 106, 584-587.	1.8	88
27	Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis and Rheumatism, 1996, 39, 671-676.	6.7	73
28	Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. American Journal of Kidney Diseases, 2010, 55, 50-60.	1.9	73
29	Role of cellular infiltrates in response to proteinuria. American Journal of Kidney Diseases, 2001, 37, S25-S29.	1.9	72
30	Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. American Journal of Physiology - Renal Physiology, 2011, 300, F245-F253.	2.7	72
31	Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. American Journal of Physiology - Renal Physiology, 2007, 293, F575-F585.	2.7	70
32	Serine proteases, inhibitors and receptors in renal fibrosis. Thrombosis and Haemostasis, 2009, 101, 656-664.	3.4	70
33	Mannose Receptor 2 Attenuates Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2012, 23, 236-251.	6.1	62
34	Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation, matrix synthesis, and proteolytic cascades. Kidney International, 1998, 53, 1182-1189.	5.2	59
35	Cysteamine Modulates Oxidative Stress and Blocks Myofibroblast Activity in CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 43-54.	6.1	58
36	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€"Children and Adolescents (SONG-KIDS) consensus workshops. Kidney International, 2020, 98, 553-565.	5.2	58

#	Article	IF	Citations
37	Urokinase Receptor Modulates Cellular and Angiogenic Responses in Obstructive Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1234-1253.	6.1	57
38	The distribution of the CR3 receptor on human cells and tissue as revealed by a monoclonal antibody. Clinical Immunology and Immunopathology, 1984, 31, 371-389.	2.0	52
39	Can renal fibrosis be reversed?. Pediatric Nephrology, 2005, 20, 1369-1375.	1.7	47
40	Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. American Journal of Kidney Diseases, 2018, 72, 547-559.	1.9	46
41	Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. American Journal of Kidney Diseases, 2019, 74, 82-94.	1.9	42
42	Standardised Outcomes in Nephrologyâ€"Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials, 2016, 17, 401.	1.6	41
43	Serine proteases, inhibitors and receptors in renal fibrosis. Thrombosis and Haemostasis, 2009, 101, 656-64.	3.4	41
44	Xanthogranulomatous Pyelonephritis in Children. Clinical Pediatrics, 1994, 33, 360-366.	0.8	40
45	Endogenous urokinase lacks antifibrotic activity during progressive renal injury. American Journal of Physiology - Renal Physiology, 2007, 293, F12-F19.	2.7	40
46	Acute kidney injury and its association with in-hospital mortality among children with acute infections. Pediatric Nephrology, 2013, 28, 2199-2206.	1.7	39
47	Presence of thyroid abnormalities in children with systemic lupus erythematosus. Journal of Pediatrics, 1991, 119, 277-279.	1.8	38
48	Tubulointerstitial nephritis. Pediatric Nephrology, 1992, 6, 572-586.	1.7	37
49	Intrarenal distribution of clusterin following reduction of renal mass. Kidney International, 1992, 41, 938-950.	5.2	36
50	Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. Journal of Pediatrics, 2017, 186, 110-117.e11.	1.8	35
51	Urokinase and its receptors in chronic kidney disease. Frontiers in Bioscience - Landmark, 2008, Volume, 5462.	3.0	34
52	Phase I Trial of Rosiglitazone in FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 39-47.	4.5	34
53	Albumin-induced apoptosis of glomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2. Nephrology Dialysis Transplantation, 2012, 27, 1330-1343.	0.7	32
54	The origin of scar-forming kidney myofibroblasts. Nature Medicine, 2013, 19, 964-966.	30.7	32

#	Article	IF	CITATIONS
55	Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice. Nephron Experimental Nephrology, 2006, 104, e23-e34.	2.2	31
56	A Novel Signaling Pathway. Journal of Biological Chemistry, 2009, 284, 29050-29064.	3.4	30
57	Expression and Function of Monocyte Chemoattractant Protein-1 in Experimental Nephrotic Syndrome. Clinical Immunology and Immunopathology, 1996, 78, 140-151.	2.0	28
58	Localization of clusterin in the epimembranous deposits of passive Heymann nephritis. Kidney International, 1991, 39, 247-252.	5.2	27
59	Expression of nephrin in acquired forms of nephrotic syndrome in childhood. Pediatric Nephrology, 2004, 19, 300-305.	1.7	25
60	Mast cells find their way to the kidney. Kidney International, 2001, 60, 375-377.	5.2	23
61	Exogenous Bone Morphogenetic Protein-7 Fails to Attenuate Renal Fibrosis in Rats with Overload Proteinuria. Nephron Experimental Nephrology, 2004, 97, e123-e135.	2.2	22
62	Vascular Endothelial Cadherin Modulates Renal Interstitial Fibrosis. Nephron Experimental Nephrology, 2012, 120, e20-e31.	2.2	22
63	Demonstration by Light Microscopy of Cytomegalovirus on a Renal Biopsy of a Renal Allograft Recipient: Confirmation by Immunohistochemistry and in situ Hybridization. Nephron, 1987, 47, 205-208.	1.8	20
64	Mitogenic Signaling of Urokinase Receptor-Deficient Kidney Fibroblasts: Actions of an Alternative Urokinase Receptor and LDL Receptor-Related Protein. Journal of the American Society of Nephrology: JASN, 2004, 15, 2090-2102.	6.1	19
65	Scraping fibrosis: UMODulating renal fibrosis. Nature Medicine, 2011, 17, 553-555.	30.7	19
66	The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: Overview of Design and Methods. Canadian Journal of Kidney Health and Disease, 2014, 1, 17.	1.1	19
67	Developing Consensus-Based Outcome Domains for Trials in Children and Adolescents With CKD: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 533-545.	1.9	19
68	Prolongation of acute renal failure in two patients with hemolytic-uremic syndrome due to excessive plasma infusion therapy. Pediatric Nephrology, 1989, 3, 420-423.	1.7	18
69	Uromodulin deficiency alters tubular injury and interstitial inflammation but not fibrosis in experimental obstructive nephropathy. Physiological Reports, 2018, 6, e13654.	1.7	17
70	Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways. Pediatric Nephrology, 2020, 35, 547-554.	1.7	17
71	Nicotinic acetylcholine receptor $\hat{l}\pm 1$ promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy. Laboratory Investigation, 2011, 91, 106-123.	3.7	16
72	Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease. American Journal of Physiology - Renal Physiology, 2011, 300, F1244-F1254.	2.7	14

#	Article	IF	Citations
73	The impact of small kidneys. Pediatric Nephrology, 2015, 30, 1501-1509.	1.7	14
74	The contribution of antibody-mediated cytotoxicity and immune-complex formation to tubulointerstitial disease in passive Heymann nephritis. Clinical Immunology and Immunopathology, 1992, 62, 42-55.	2.0	12
75	Renal remodelling in dietary protein modified rat polycystic kidney disease. Pediatric Nephrology, 1999, 13, 567-570.	1.7	12
76	Decreased plasma fibronectin levels in children with hemolytic-uremic syndrome. American Journal of Medicine, 1985, 78, 549-554.	1.5	11
77	Intraglomerular leukocyte recruitment during nephrotoxic serum nephritis in rats. Clinical Immunology and Immunopathology, 1990, 57, 441-458.	2.0	11
78	Ramping up endogenous defences against chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 1174-1177.	0.7	9
79	Tubulo \tilde{A}^{\otimes} nterstitial Nephritis during the Heterologous Phase of Nephrotoxic Serum Nephritis. Nephron, 1991, 59, 304-313.	1.8	8
80	Impact of training nephrologists from developing nations and strategies for sustaining a training program in its fourth decade. Kidney International, 2021, 99, 1073-1076.	5.2	7
81	A study by immunofluorescence microscopy of the NC1 domain of collagen type IV in glomerular basement membranes of two patients with hereditary nephritis. Virchows Archiv A, Pathological Anatomy and Histopathology, 1990, 416, 205-212.	1.4	6
82	Setting New Directions for Research in Childhood Nephrotic Syndrome: Results From a National Workshop. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811770338.	1.1	6
83	The TGF-Î ² Route to Renal Fibrosis Is Not Linear: The miR-21 Viaduct. Journal of the American Society of Nephrology: JASN, 2011, 22, 1573-1575.	6.1	4
84	Pathophysiology of Progressive Renal Disease. , 2009, , 1631-1659.		4
85	Interstitial Nephritis in Children. , 2016, , 1013-1036.		4
86	Pulmonary Hemorrhage and Necrotizing Glomerulonephritis Without Glomerular Immune Deposits: Report of Two Cases. American Journal of Kidney Diseases, 1991, 18, 257-263.	1.9	3
87	Perspectives of Clinicians on Shared Decision Making in Pediatric CKD: A Qualitative Study. American Journal of Kidney Diseases, 2022, 80, 241-250.	1.9	3
88	An Introduction to Frontiers in Nephrology. Journal of the American Society of Nephrology: JASN, 2002, 13, 2185-2185.	6.1	2
89	Round 3 at JASN (2001 to 2007): Recollections of the Third Editorial Team. Journal of the American Society of Nephrology: JASN, 2010, 21, 1409-1410.	6.1	2
90	Patient and caregiver perspectives on blood pressure in children with chronic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1330-1339.	0.7	2

ALLISON A EDDY

#	Article	IF	CITATIONS
91	Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. Pediatric Nephrology, 2023, 38, 249-260.	1.7	2
92	Subepithelial Humps and Microthrombi: Looking for a Mechanism. American Journal of Kidney Diseases, 2006, 47, 365-370.	1.9	1
93	Interstitial Nephritis., 2008,, 527-538.		O